

Peter Verhamme

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1772056/publications.pdf>

Version: 2024-02-01

176
papers

13,080
citations

70961

41
h-index

24179

110
g-index

177
all docs

177
docs citations

177
times ranked

12889
citing authors

#	ARTICLE	IF	CITATIONS
1	Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 369, 1406-1415.	13.9	1,607
2	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576
3	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2018, 378, 615-624.	13.9	1,237
4	Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. <i>New England Journal of Medicine</i> , 2017, 377, 431-441.	13.9	858
5	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	13.9	692
6	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	13.9	687
7	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , 2020, 4, 4693-4738.	2.5	636
8	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 1211-1222.	13.9	577
9	Circulating Oxidized LDL Is a Useful Marker for Identifying Patients With Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 844-848.	1.1	469
10	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2306-2315.	1.2	296
11	Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 409.	3.8	265
12	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. <i>JAMA Internal Medicine</i> , 2015, 175, 1474.	2.6	180
13	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1439-1449.	1.8	154
14	Abelacimab for Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2021, 385, 609-617.	13.9	143
15	Adhesion of <i>Staphylococcus aureus</i> to the vessel wall under flow is mediated by von Willebrand factor-binding protein. <i>Blood</i> , 2014, 124, 1669-1676.	0.6	96
16	<i>Staphylococcus aureus</i> endocarditis: distinct mechanisms of bacterial adhesion to damaged and inflamed heart valves. <i>European Heart Journal</i> , 2019, 40, 3248-3259.	1.0	92
17	Inactive Matrix Gla Protein Is Causally Related to Adverse Health Outcomes. <i>Hypertension</i> , 2015, 65, 463-470.	1.3	84
18	Edoxaban for treatment of venous thromboembolism in patients with cancer. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1268-1276.	1.8	79

#	ARTICLE	IF	CITATIONS
19	Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. <i>Thrombosis Journal</i> , 2014, 12, 21.	0.9	78
20	Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. <i>Thrombosis Research</i> , 2015, 136, 749-753.	0.8	78
21	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. <i>Kidney International Reports</i> , 2017, 2, 1066-1075.	0.4	77
22	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. <i>Blood Advances</i> , 2018, 2, 788-796.	2.5	71
23	Branched-Chain Amino Acids as Critical Switches in Health and Disease. <i>Hypertension</i> , 2018, 72, 1012-1022.	1.3	63
24	Fibrin formation by staphylothrombin facilitates <i>Staphylococcus aureus</i> -induced platelet aggregation. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1107-1121.	1.8	62
25	Duration of anticoagulation after venous thromboembolism in real world clinical practice. <i>Thrombosis Research</i> , 2015, 135, 666-672.	0.8	62
26	A Human Platelet Receptor Protein Microarray Identifies the High Affinity Immunoglobulin E Receptor Subunit β (Fc μ R1 β) as an Activating Platelet Endothelium Aggregation Receptor 1 (PEAR1) Ligand *. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 1265-1274.	2.5	62
27	Staphylokinase Control of <i>Staphylococcus aureus</i> Biofilm Formation and Detachment Through Host Plasminogen Activation. <i>Journal of Infectious Diseases</i> , 2016, 213, 139-148.	1.9	61
28	The Role of Staphylothrombin-Mediated Fibrin Deposition in Catheter-Related <i>Staphylococcus aureus</i> Infections. <i>Journal of Infectious Diseases</i> , 2013, 208, 92-100.	1.9	59
29	Coagulation: At the heart of infective endocarditis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 995-1008.	1.9	59
30	The urinary proteome as correlate and predictor of renal function in a population study. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2260-2268.	0.4	57
31	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. <i>Lancet Haematology</i> , 2016, 3, e267-e275.	2.2	55
32	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016, 3, e228-e236.	2.2	55
33	Bacterial pathogens activate plasminogen to breach tissue barriers and escape from innate immunity. <i>Critical Reviews in Microbiology</i> , 2016, 42, 866-882.	2.7	53
34	Hemostasis and inflammation: two of a kind?. <i>Thrombosis Journal</i> , 2009, 7, 15.	0.9	52
35	Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. <i>British Journal of Haematology</i> , 2021, 192, 1100-1105.	1.2	51
36	Rationale for azithromycin in COVID-19: an overview of existing evidence. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000806.	1.2	49

#	ARTICLE	IF	CITATIONS
37	Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. <i>Thrombosis Research</i> , 2016, 144, 62-68.	0.8	47
38	Pragmatic approach to manage new oral anticoagulants in patients undergoing dental extractions: a prospective case-control study. <i>Clinical Oral Investigations</i> , 2017, 21, 2183-2188.	1.4	47
39	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. <i>American Journal of Medicine</i> , 2017, 130, 588-595.	0.6	45
40	Vitamin K Dependent Protection of Renal Function in Multi-ethnic Population Studies. <i>EBioMedicine</i> , 2016, 4, 162-169.	2.7	44
41	Dabigatran Inhibits <i>Staphylococcus aureus</i> Coagulase Activity. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4248-4250.	1.8	43
42	Left Ventricular Structure and Function in Relation to Environmental Exposure to Lead and Cadmium. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	42
43	Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. <i>Thorax</i> , 2021, 76, 1002-1009.	2.7	41
44	Shear-Resistant Binding to von Willebrand Factor Allows <i>Staphylococcus lugdunensis</i> to Adhere to the Cardiac Valves and Initiate Endocarditis. <i>Journal of Infectious Diseases</i> , 2016, 213, 1148-1156.	1.9	38
45	Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. <i>European Respiratory Journal</i> , 2022, 59, 2101724.	3.1	38
46	Plasminogen activation by staphylokinase enhances local spreading of <i>S. aureus</i> in skin infections. <i>BMC Microbiology</i> , 2014, 14, 310.	1.3	36
47	Platelet endothelial aggregation receptor-1: a novel modifier of neoangiogenesis. <i>Cardiovascular Research</i> , 2015, 108, 124-138.	1.8	36
48	Coagulase Activity by <i>Staphylococcus aureus</i> : A Potential Target for Therapy?. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 433-444.	1.5	35
49	Left ventricular function in relation to chronic residential air pollution in a general population. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1416-1428.	0.8	35
50	Reduced-Dose Intravenous Thrombolysis for Acute Intermediateâ€“High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International Thrombolysis (PEITHO)-3 trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 857-866.	1.8	35
51	Urinary Proteome and Systolic Blood Pressure as Predictors of 5-Year Cardiovascular and Cardiac Outcomes in a General Population. <i>Hypertension</i> , 2015, 66, 52-60.	1.3	33
52	Desphospho-uncarboxylated matrix Gla protein is a novel circulating biomarker predicting deterioration of renal function in the general population. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1122-1128.	0.4	33
53	Vitamin Kâ€“Dependent Matrix Gla Protein as Multifaceted Protector of Vascular and Tissue Integrity. <i>Hypertension</i> , 2019, 73, 1160-1169.	1.3	33
54	Cardiovascular End Points and Mortality Are Not Closer Associated With Central Than Peripheral Pulsatile Blood Pressure Components. <i>Hypertension</i> , 2020, 76, 350-358.	1.3	33

#	ARTICLE	IF	CITATIONS
55	Tranexamic acid for the prevention and treatment of bleeding in surgery, trauma and bleeding disorders: a narrative review. <i>Thrombosis Journal</i> , 2021, 19, 54.	0.9	33
56	Early Use of Echocardiography in Patients With Acute Pulmonary Embolism: Findings From the RIETE Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009042.	1.6	31
57	Clinical implications of incidental venous thromboembolism in cancer patients. <i>European Respiratory Journal</i> , 2020, 55, 1901697.	3.1	31
58	Lemierre Syndrome: Clinical Update and Protocol for a Systematic Review and Individual Patient Data Meta-analysis. <i>Hamostaseologie</i> , 2019, 39, 076-086.	0.9	30
59	Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 132-140.	1.8	30
60	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016, 3, e437-e445.	2.2	29
61	A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2015, 3, 243-250.e1.	0.9	28
62	Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 116, 747-753.	1.8	28
63	Glomerular function in relation to circulating adhesion molecules and inflammation markers in a general population. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 426-435.	0.4	27
64	Anti-thrombotic therapy in infective endocarditis. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1203-1219.	0.6	26
65	Tissue Plasminogen Activator Coating on Implant Surfaces Reduces <i>Staphylococcus aureus</i> Biofilm Formation. <i>Applied and Environmental Microbiology</i> , 2016, 82, 394-401.	1.4	25
66	Shear Stress and VE-Cadherin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2174-2183.	1.1	25
67	Variation of PEAR1 DNA methylation influences platelet and leukocyte function. <i>Clinical Epigenetics</i> , 2019, 11, 151.	1.8	25
68	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. <i>Stroke</i> , 2021, 52, 2096-2105.	1.0	25
69	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 646-656.	1.8	25
70	Characteristics and Determinants of the Sublingual Microcirculation in Populations of Different Ethnicity. <i>Hypertension</i> , 2015, 65, 993-1001.	1.3	24
71	A Urinary Fragment of Mucin-1 Subunit $\hat{\pm}$ Is a Novel Biomarker Associated With Renal Dysfunction in the General Population. <i>Kidney International Reports</i> , 2017, 2, 811-820.	0.4	24
72	Von Willebrand factor and ADAMTS13 impact on the outcome of <i>Staphylococcus aureus</i> sepsis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 722-731.	1.9	24

#	ARTICLE	IF	CITATIONS
73	Association of Fatal and Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure. <i>Hypertension</i> , 2021, 77, 39-48.	1.3	24
74	Active PAI-1 as marker for venous thromboembolism: Caseâ€“control study using a comprehensive panel of PAI-1 and TAFI assays. <i>Thrombosis Research</i> , 2014, 134, 1097-1102.	0.8	23
75	Assessment of the Dual Role of Clumping Factor A in <i>S. Aureus</i> Adhesion to Endothelium in Absence and Presence of Plasma. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1230-1241.	1.8	23
76	Diastolic left ventricular function in relation to circulating metabolic biomarkers in a population study. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 22-32.	0.8	23
77	Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. <i>Clinical Therapeutics</i> , 2010, 32, 1205-1220.	1.1	22
78	Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. <i>PLoS ONE</i> , 2016, 11, e0167582.	1.1	22
79	Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. <i>EBioMedicine</i> , 2021, 66, 103288.	2.7	21
80	<i>Staphylococcus aureus</i> and Neutrophil Extracellular Traps: The Master Manipulator Meets Its Match in Immunothrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 261-276.	1.1	21
81	Pulmonary embolism: Epidemiology and registries. <i>Presse Medicale</i> , 2015, 44, e377-e383.	0.8	20
82	Conventional and Ambulatory Blood Pressure as Predictors of Retinal Arteriolar Narrowing. <i>Hypertension</i> , 2016, 68, 511-520.	1.3	20
83	Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. <i>Blood Pressure</i> , 2017, 26, 321-331.	0.7	20
84	Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 438-447.e4.	2.3	20
85	Association between cognition and the retinal microvasculature in 11-year old children born preterm or at term. <i>Early Human Development</i> , 2018, 118, 1-7.	0.8	20
86	Local haemostatic measures after tooth removal in patients on antithrombotic therapy: a systematic review. <i>Clinical Oral Investigations</i> , 2019, 23, 1695-1708.	1.4	20
87	Dabigatran-Associated Spontaneous Acute Cervical Epidural Hematoma. <i>World Neurosurgery</i> , 2015, 83, 257-258.	0.7	18
88	Dextran sulfate triggers platelet aggregation via direct activation of PEAR1. <i>Platelets</i> , 2016, 27, 365-372.	1.1	18
89	Central Systolic Augmentation Indexes and Urinary Sodium in a White Population. <i>American Journal of Hypertension</i> , 2013, 26, 95-103.	1.0	17
90	Inactive matrix Gla protein is a novel circulating biomarker predicting retinal arteriolar narrowing in humans. <i>Scientific Reports</i> , 2018, 8, 15088.	1.6	17

#	ARTICLE	IF	CITATIONS
91	A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. <i>Trials</i> , 2020, 21, 981.	0.7	17
92	Diastolic Left Ventricular Function in Relation to Circulating Metabolic Biomarkers in a General Population. <i>Journal of the American Heart Association</i> , 2016, 5, e002681.	1.6	16
93	Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. <i>PLoS ONE</i> , 2018, 13, e0194673.	1.1	16
94	Retinal microvascular diameter, a hypertension-related trait, in ECG-gated vs. non-gated images analyzed by IVAN and SIVA. <i>Hypertension Research</i> , 2016, 39, 886-892.	1.5	15
95	Targeting Coagulase Activity in <i>Staphylococcus aureus</i> Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition. <i>Thrombosis and Haemostasis</i> , 2018, 118, 818-829.	1.8	15
96	The risk of nephrolithiasis is causally related to inactive matrix Gla protein, a marker of vitamin K status: a Mendelian randomization study in a Flemish population. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 514-522.	0.4	15
97	Definition of bleeding events in studies evaluating prophylactic antithrombotic therapy in pregnant women: A systematic review and a proposal from the ISTH SSC. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1979-1988.	1.9	15
98	Relative and Absolute Risk to Guide the Management of Pulse Pressure, an Age-Related Cardiovascular Risk Factor. <i>American Journal of Hypertension</i> , 2021, 34, 929-938.	1.0	15
99	Renal glomerular dysfunction in relation to retinal arteriolar narrowing and high pulse pressure in seniors. <i>Hypertension Research</i> , 2016, 39, 138-143.	1.5	14
100	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , 2017, 149, 29-37.	0.8	14
101	Central Hemodynamics in Relation to Circulating Desphospho- α -Carboxylated Matrix Gla Protein: A Population Study. <i>Journal of the American Heart Association</i> , 2019, 8, e011960.	1.6	14
102	The Expression of von Willebrand Factor-Binding Protein Determines Joint-Invasive Capacity of <i>Staphylococcus aureus</i> , a Core Mechanism of Septic Arthritis. <i>MBio</i> , 2020, 11, .	1.8	14
103	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1097-1106.	1.8	14
104	Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. <i>Thrombosis and Haemostasis</i> , 2013, 109, 1091-1098.	1.8	13
105	Gender differences in cancer patients with acute venous thromboembolism. <i>Thrombosis Research</i> , 2015, 135, S12-S15.	0.8	13
106	PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population. <i>BMC Medical Genetics</i> , 2017, 18, 45.	2.1	13
107	Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. <i>European Respiratory Journal</i> , 2019, 53, 1801677.	3.1	13
108	Prevalence of Acute Pulmonary Embolism at Autopsy in Patients With COVID-19. <i>American Journal of Cardiology</i> , 2022, 171, 159-164.	0.7	13

#	ARTICLE	IF	CITATIONS
109	Direct Oral Anticoagulants for Acute Venous Thromboembolism. <i>Circulation</i> , 2014, 129, 725-727.	1.6	12
110	Coronary risk in relation to genetic variation in MEOX2 and TCF15 in a Flemish population. <i>BMC Genetics</i> , 2015, 16, 116.	2.7	12
111	Impact of Thrombus Sidedness on Presentation and Outcomes of Patients with Proximal Lower Extremity Deep Vein Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 341-347.	1.5	12
112	ECG Voltage in Relation to Peripheral and Central Ambulatory Blood Pressure. <i>American Journal of Hypertension</i> , 2018, 31, 178-187.	1.0	12
113	Belgian clinical guidance on anticoagulation management in hospitalised and ambulatory patients with COVID-19. <i>Acta Clinica Belgica</i> , 2020, , 1-6.	0.5	12
114	Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia. <i>Thrombosis Research</i> , 2020, 195, 139-145.	0.8	12
115	A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 24, 1-5.	1.0	11
116	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , 2018, 168, 121-129.	0.8	11
117	Renal function in relation to low-level environmental lead exposure. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 941-946.	0.4	11
118	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103125.	2.0	11
119	Tranexamic acid and bleeding in patients treated with non-vitamin K oral anticoagulants undergoing dental extraction: The EXTRACT-NOAC randomized clinical trial. <i>PLoS Medicine</i> , 2021, 18, e1003601.	3.9	11
120	Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?. <i>TH Open</i> , 2020, 04, e446-e456.	0.7	11
121	Absence of Pear1 does not affect murine platelet function in vivo. <i>Thrombosis Research</i> , 2016, 146, 76-83.	0.8	10
122	Urinary peptidomic biomarkers of renal function in heart transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1336-1343.	0.4	10
123	Retinal Microvasculature in Relation to Central Hemodynamics in a Flemish Population. <i>Hypertension</i> , 2019, 74, 606-613.	1.3	10
124	Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation. <i>European Journal of Heart Failure</i> , 2019, 21, 129-131.	2.9	10
125	Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2”azithromycin trial. <i>Trials</i> , 2021, 22, 126.	0.7	10
126	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3008-3017.	1.9	10

#	ARTICLE	IF	CITATIONS
127	Epidemiological and histological findings implicate matrix Gla protein in diastolic left ventricular dysfunction. PLoS ONE, 2018, 13, e0193967.	1.1	10
128	Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. ESC Heart Failure, 2022, 9, 685-694.	1.4	10
129	In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions. Journal of Visualized Experiments, 2015, , e52862.	0.2	9
130	Urinary Proteomic Profile of Arterial Stiffness Is Associated With Mortality and Cardiovascular Outcomes. Journal of the American Heart Association, 2022, 11, e024769.	1.6	9
131	Venous thromboembolism in centenarians: Findings from the RIETE registry. European Journal of Internal Medicine, 2016, 36, 62-66.	1.0	8
132	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis, 2017, 117, 2406-2414.	1.8	8
133	Reproducibility of Retinal Microvascular Traits Decoded by the Singapore I Vessel Assessment Software Across the Human Age Range. American Journal of Hypertension, 2018, 31, 438-449.	1.0	8
134	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. Thrombosis and Haemostasis, 2019, 119, 576-585.	1.8	8
135	Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol. Blood Pressure, 2021, 30, 269-281.	0.7	8
136	The novel proteomic signature for cardiac allograft vasculopathy. ESC Heart Failure, 2022, 9, 1216-1227.	1.4	8
137	Mechanical and structural properties of leukocyte- and platelet-rich fibrin membranes: An in vitro study on the impact of anticoagulant therapy. Journal of Periodontal Research, 2020, 55, 686-693.	1.4	7
138	Two-Year Responses of Heart Rate and Heart Rate Variability to First Occupational Lead Exposure. Hypertension, 2021, 77, 1775-1786.	1.3	7
139	Normal-tension glaucomatous optic neuropathy is related to blood pressure variability in the Maracaibo Aging Study. Hypertension Research, 2021, 44, 1105-1112.	1.5	7
140	Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study. Nephrology Dialysis Transplantation, 2021, 36, 884-889.	0.4	7
141	A pilot trial of microplasmin in patients with long-term venous access catheter thrombosis. Journal of Thrombosis and Thrombolysis, 2009, 28, 477-481.	1.0	6
142	Non-vitamin K oral anticoagulants in adults with congenital heart disease: quod non?. European Heart Journal, 2020, 41, 4178-4180.	1.0	6
143	Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry. TH Open, 2020, 04, e236-e244.	0.7	6
144	Association between reperfusion therapy and outcomes in patients with acute pulmonary embolism and right heart thrombi. European Respiratory Journal, 2020, 56, 2000538.	3.1	6

#	ARTICLE	IF	CITATIONS
145	A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study. <i>Blood</i> , 2017, 130, LBA-6-LBA-6.	0.6	6
146	Carotid intima-media thickness: more than a research tool?. <i>Acta Cardiologica</i> , 2010, 65, 59-66.	0.3	6
147	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	1.4	6
148	Conventional and Ambulatory Blood Pressure as Predictors of Diastolic Left Ventricular Function in a Flemish Population. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	5
149	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. <i>TH Open</i> , 2018, 02, e1-e7.	0.7	5
150	Implementing Automated Office Blood Pressure Measurement. <i>Hypertension</i> , 2019, 74, 441-449.	1.3	5
151	Retinal and Renal Microvasculature in Relation to Central Hemodynamics in 11-Year-Old Children Born Preterm or At Term. <i>Journal of the American Heart Association</i> , 2020, 9, e014305.	1.6	5
152	Phase I Clinical Trial of a Novel, Long-Acting Antithrombotic Drug: A Human Monoclonal Antibody Partially Inhibiting FVIII Activity.. <i>Blood</i> , 2007, 110, 312-312.	0.6	5
153	Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO). <i>ERJ Open Research</i> , 2022, 8, 00610-2021.	1.1	5
154	Open-Angle Glaucomatous Optic Neuropathy Is Related to Dips Rather Than Increases in the Mean Arterial Pressure Over 24-H. <i>American Journal of Hypertension</i> , 2022, 35, 703-714.	1.0	5
155	Intermittent pneumatic compression on top of pharmacological thromboprophylaxis in intensive care: added value or added cost?. <i>Journal of Thoracic Disease</i> , 2019, 11, 1734-1737.	0.6	4
156	A comprehensive report of long-term outcomes after catheter-directed thrombolysis for occluded infrainguinal bypass grafts. <i>Journal of Vascular Surgery</i> , 2019, 70, 1205-1216.	0.6	4
157	The Dangerous Liaisons between Chronic Obstructive Pulmonary Disease and Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2020, 120, 363-365.	1.8	4
158	Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 337, 9-15.	0.8	4
159	A RIETE registry analysis of patients with upper extremity deep vein thrombosis and thoracic outlet syndrome. <i>Thrombosis Research</i> , 2022, 213, 65-70.	0.8	4
160	Thromboprophylaxis in COVID-19: Weight and severity adjusted intensified dosing. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12683.	1.0	4
161	Mechanical properties and cellular content of leukocyte- and platelet-rich fibrin membranes of patients on antithrombotic drugs. <i>Journal of Periodontal Research</i> , 2022, , .	1.4	4
162	Central hemodynamics in relation to low-level environmental lead exposure. <i>Blood Pressure</i> , 2020, 29, 157-167.	0.7	3

#	ARTICLE	IF	CITATIONS
163	Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12566.	1.0	3
164	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. Blood, 2012, 120, 499-499.	0.6	3
165	Apixaban in a porcine model of mechanical valve thrombosis in pulmonary positionâ€”a pilot study. Interactive Cardiovascular and Thoracic Surgery, 2022, 35, .	0.5	2
166	Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12748.	1.0	2
167	Maxillofacial and oral surgery in patients with thrombophilia: safe territory for the oral surgeon? A single-center retrospective study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2021, 132, 514-522.	0.2	1
168	D-Dimer Levels and Risk of Recurrence Following Provoked Venous Thromboembolism: Findings from the Riete Registry. Blood, 2018, 132, 3810-3810.	0.6	1
169	Association of colorectal cancer with genetic and epigenetic variation in PEAR1â€”A population-based cohort study. PLoS ONE, 2022, 17, e0266481.	1.1	1
170	Abstract 16418: Reinitiation of Antithrombotic Therapy After Emergency Procedures or After an Uncontrolled or Life Threatening Bleeding Event. Initial Experience From the Re-verse Ad Trial. Circulation, 2015, 132, .	1.6	1
171	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. Circulation, 2022, 145, 1875-1877.	1.6	1
172	Antiplatelet treatment in peripheral arterial disease. , 2001, , 458-470.		0
173	Cerebral small vessel diseases are better associated with ambulatory than office blood pressure measurements. Alzheimer's and Dementia, 2020, 16, e045987.	0.4	0
174	Diastolic left ventricular function in relation to the retinal microvascular fractal dimension in a Flemish population. Hypertension Research, 2021, 44, 446-453.	1.5	0
175	Antithrombotic Treatment and Outcomes of Splanchnic Vein Thrombosis in an International Prospective Registry: Results of 2-Year Follow-up. Blood, 2014, 124, 592-592.	0.6	0
176	Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. Blood, 2014, 124, LBA-1-LBA-1.	0.6	0